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protection and are poorly prepared to build a life for
themselves. Attempts to survive often lead to their trading
any type of assistance (emotional and/or physical) for sexual
favours, prostitution and criminal activities. Child abuse is a
serious problem that demands broad multidisciplinary and
inter-sectoral approaches. Recovery, a publication from the
practical ministries and Kwazulu-Natal Programme for the
Survivors of Violence, reports that in 1995, 16.2% of HIV-
positive people were reported to be under the age of 19
years.20 The number of children affected by political violence
in Kwazulu-Natal alone is reported by them to be 26 790
(and these figures do not reflect child abuse). In addition,
Recovery states that in South Africa ± 14.3 million children
under the age of 15 years are living with caregivers who
earn or receive less than R8DD per month. The impact of
ongoing community violence on children has been neglected
in historically disadvantaged communities!' Substance
abuse, mainly alcohol, is a contributing factor in many cases
of violence, including child abuse.22 Populations of children
evaluated for suspected child sexual abuse are probably at
a greater risk of exposure to the HIV virus than are other
children.23 The subservient role of women in society,
temporality of bonding and other gender issues, plus family
fragmentation, are important contributing factors in cases of
child abuse!'
In our profession we sometimes encounter these children
in hospitals, or know of them as names on laboratory forms
or as anonymous bodies on autopsy tables. If they are
physically presented to us we feel a mixture of indignation,
outrage, involvement, voyeurism, frustration, reluctance and
immeasurable pity. When they come in for examination with
their J88 forms we would rather be somewhere else. But
they are here, rivalling the prose of Hugo and Dickens, they
are here. And, for the majority of these child victims in South
Africa, there is no place of safety.
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countries - do we know
enough?
The article by Matchaba and Chapanduka' calls for the
urgent need for antiretroviral therapy in HIV-infected
pregnant women to reduce mother-to-infant transmission in
developing countries. They largely make use of the results of
the AIDS Clinical Trials Group Protocol 076 (ACTG 076)
study to make their point! However they do not take into
account the realities of the health care situation in
developing countries, nor do they discuss the logistics of
applying this regimen in countries such as our. own. These
realities include the following facts.'
1. The majority of women only attend antenatal clinics
very late in pregnancy, too late to receive the ACTG 076
regimen.3
2. A significant proportion of prenatal care and delivery
occurs in primary health care settings where facilities for
providing intravenous therapy may be lacking_
3. There is poor compliance due to infrequent visits both
before and after delivery.
4. The ACTG 076 regimen costs approximately US$1 000
per month: introduction of this regimen includes the cost of
routine screening, employment of counsellors and the
establisr,ment of laboratories where costly new techniques
are used for the early diagnosis of HIV infection in infants.
Severe financial constraints in South Africa and other
developing countries preclude the' use of this regimen.
5. The ACTG 076 study was conducted on women who
were not breast-feeding their babies. The efficacy of the 076
regimen in breast-feeding communities has not been tested,
and the financial costs and effect on infant morbidity of
alternative feeding methods, such as subsidised fonmula
feeds, in developing countries need to be assessed if
women are to be advised against breast-feeding.
Matchaba and Chapanduka have also misinterpreted the
results of a short-regimen antiretroviral study from Durban
(submitted for publication), which they quote as showing a
significant reduction in mother-to-infant transmission. This
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was not an efficacy study, but rather a pharmacokinetics
and safety study of zidovudine (An) and lamivudine (3TC)
for 14 days in 20 mothers in late pregnancy, and in their
neonates for a week. The lower rate of mother-to-infant
transmission in a study of 20 women in comparison with the
vertical transmission rate in a retrospective cohort study
cannot be used as argument for the routine use of
antiretroviral therapy in HIV-positive pregnant women.
The World Health Organisation and the Joint United
Nations Programme on HIV/AIOS (UNAIOS) have recognised
that the ACTG 076 regimen is not applicable in those parts of
the world where most mother-to-infant transmissions occur,
and have called for placebo-controlled trials as the best
option for obtaining rapid and scientifically valid results.
These trials should include antiretroviral agents given for short
durations in late pregnancy, in labour, and to neonates for 1
or 2 days; oral therapy in labour only; and combinations of
different antiretroviral drugs. An ongoing trial, PETRA
(perinatal transmission), supported by UNAIOS but designed
in conjunction with African scientists, is currently in progress
in a number of African centres, including Durban and
Johannesburg. The aim of this placebo-controlled trial is to
evaluate whether shorter regimens, which can realistically be
implemented in test countries, are better than no treatment at
all. Subanalysis of the ACTG 076 study has shown that less
than 12-week regimens are as effective as those of more than
12 weeks. This, however, does not give any indication of the
efficacy of a 2 - 3-week regimen.
Another debatable issue not included in the article by
Matchaba and Chapanduka but that needs to be mentioned
is the ethical considerations of placebo-controlled trials in
developing countries.' Critics maintain that nearly all such
trials violate accepted international ethical standards
because participating control groups are only offered
placebos, as opposed to being given antiretroviral therapy
that is known to be effective.
The debate has led to comparisons with the Tuskegee
study, in which effective treatment was withheld from some
400 African Americans without their knowledge in order to
establish the natural history of syphilis. This study has been
described as a 'metaphor for racism in medicine.'
Comparison with vertical transmission HIV studies in
pregnancy, however, is unfair. Trials in Africa are frequently
conducted by African scientists who have contributed
significantly to the design of the studies and who are
concerned for the welfare of their particular communities. In
addition, local government authorities are informed of all
such studies and ethical permission, usually from university
ethical committees, will have been obtained. Subjects are
informed of the existence of a placebo arm and give written
consent. They are not intentionally deceived or deprived of
treatments that are affordable, readily available and known
to be effective, as was the case in the Tuskegee experiment.
Placebo-controlled antiretroviral trials in developing
countries will continue until a short applicable regimen is
found to be effective in reducing mother-to-infant
transmission.
The level of information provided to participant women
and consent procedures are two further criticisms of these
studies. Certainly in the trials conducted in South Africa,
women were fully informed regarding the benefits and
disadvantages involved, including the placebo component.
Criticism of HIV trials in developing countries has raised
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the question of whether these studies could be undertaken
in the First World. The question of double standards,
however, lies not in the way the trials are being conducted,
but in unequal access to medicines in different countries.
It is our conclusion that before demands are made for the
immediate use of antiretrovirals in pregnancy, an interaction
is urgently needed between researchers, health authorities,
pharmaceutical companies and global institutional
programmes such as UNAIOS. This interaction would help
prepare the infrastructure for the application of a short and
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Preventing perinatal HIV
transmission - now is the
time to act!
We thank Moodley et al. for their response to our paper.'
We are pleased to note that they concur that the major
intervention in the prevention of perinatal HIV transmission is
AZT use. In our paper we stated the need for the
development of local protocols, outlined the reasons for this
and certainly did not recommend that protocol ACTG 0762
be used here. We believe that all the 'realities of the situation
in respect of health care in developing countries' referred to
by Moodley et al. in their response were SUfficiently
addressed in our original paper. The breast-feeding issue
was also addressed at length.
They seem, however, to have missed two important issues
raised by ourselves. Instead they focused on the issue of
placebo-controlled trials, which we elected not to raise in
our editorial' because of the volatile nature of the topic. We
did not want to distract from the main thrust of our editorial,
namely that 'now is the right time to act' in dealing with
perinatal HIV transmission using zidovudine (AZT) as part of
the national maternal and child health care (MCHC)
programme. We will, however, address the issue of placebo
trials in perinatal HIV transmission later in this article.
. The first point they overlooked was the length of time it is
taking to get protocols or interim results from the local
studies being done. During this time perinatal transmission
of HIV continues unabated.
